Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bitopertin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 known ✓ | P48067 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 1.00 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bitopertin SCHEMBL29985866 | 1.00 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 | |
| Bitopertin SCHEMBL3772885 | 1.00 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 | |
| Bitopertin SCHEMBL29363611 | 1.00 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 | |
| Bitopertin SCHEMBL561853 | 1.00 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL12172477 | 0.94 | SLC6A9 (0.88) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL4424343 | 0.93 | SLC6A9 (0.87) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL562102 | 0.91 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL8195740 | 0.91 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL18502986 | 0.91 | SLC6A9 (0.83) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL5042089 | 0.88 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106163520-B | GLYT1 inhibitors for the treatment of hematological disorders | 豪夫迈·罗氏有限公司 | 2019-12-13 | — | — | CN | claimed |
| EP-3137073-B1 | GLYT1 INHIBITORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2018-06-06 | — | — | EP | claimed |
| US-9877963-B2 | GlyT1 inhibitors for use in the treatment of hematological disorders | HOFFMANN-LA ROCHE INC. (US) | 2018-01-30 | — | — | US | claimed |
| EP-3137073-A1 | GLYT1 INHIBITORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | F. Hoffmann-La Roche AG (CH) | 2017-03-08 | — | — | EP | claimed |
| US-20170042888-A1 | GLYT1 INHIBITORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2017-02-16 | — | — | US | claimed |
| EP-2962106-A1 | AGENTS, KITS AND METHODS FOR COMPLEMENT FACTOR H-RELATED PROTEIN 1 DETECTION | Roche Diagnostics GmbH (DE) | 2016-01-06 | — | — | EP | claimed |
| US-20150355199-A1 | AGENTS, KITS AND METHODS FOR COMPLEMENT FACTOR H-RELATED PROTEIN 1 DETECTION | ROCHE DIAGNOSTICS GMBH (DE) | 2015-12-10 | — | — | US | claimed |
| WO-2015165842-A1 | GLYT1 INHIBITORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-05 | — | — | WO | claimed |
| EP-2114405-B1 | methylparaben cocrystal form \"A\" of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-[5-methanesulfonyl-2- ((S) -2,2,2-trifluoro- 1 -methyl-ethoxy) -phenyl] -methanone | HOFFMANN LA ROCHE (CH) | 2015-03-11 | — | — | EP | claimed |
| EP-2603219-B1 | COMBINATION OF GLYT1 COMPOUND WITH ANTIPSYCHOTICS | HOFFMANN LA ROCHE (CH) | 2014-09-17 | — | — | EP | claimed |
| US-8039473-B2 | Solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | claimed |
| US-20100311971-A1 | SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE | BUBENDORF ANDRE | 2010-12-09 | — | — | US | claimed |
| EP-2114405-A1 | CRYSTALLINE FORMS GLYT1 | F. Hoffmann-Roche AG (CH) | 2009-11-11 | — | — | EP | claimed |
| US-20080214561-A1 | SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE | HOFFMANN-LA ROCHE, INC. | 2008-09-04 | — | — | US | claimed |
| WO-2008080821-A1 | CRYSTALLINE FORMS GLYT1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | WO | claimed |
| US-7319099-B2 | Such as 1-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl benzoyl)-piperazin-1-yl]-phenyl}-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | claimed |
| EP-1656361-B1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | claimed |
| EP-1656361-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | claimed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | claimed |
| WO-2005014563-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209241-A1 | Benzoyl-piperazine derivatives | SLC1A2, SLC18A2, SLC6A7 | SLC6A9 82/4885KCNH2 719/4885SLC6A5 9/4885 |
| US-20100311971-A1 | SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE | SNCA, PSEN2, ACHE | SLC6A9 3658/4885KCNH2 165/4885SLC6A5 1095/4885 |
| US-20080214561-A1 | SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE | SNCA, PSEN2, ACHE | SLC6A9 3658/4885KCNH2 165/4885SLC6A5 1095/4885 |
| US-20170042888-A1 | GLYT1 INHIBITORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | SLC40A1, GFPT1, HBG1 | SLC6A9 121/4885KCNH2 3010/4885SLC6A5 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.